Our Services
Medical Information
Helpful Resources
Published on: 5/6/2026
Panretinal photocoagulation (PRP) treats neovascular glaucoma by using targeted peripheral retinal laser to reduce ischemia-driven VEGF production. This causes abnormal iris and angle blood vessels to regress, reopens the drainage angle, lowers intraocular pressure (IOP), and prevents synechiae—helping preserve vision. PRP is an outpatient procedure commonly combined with anti-VEGF injections and IOP-lowering medications to stabilize retinal disease and reduce the need for surgery.
Key considerations include the risk of peripheral vision loss, the importance of thorough evaluation and follow-up, and the potential need for additional treatments.
Because glaucoma symptoms can overlap with other serious eye conditions—and early detection dramatically improves outcomes—it's worth understanding what your specific symptoms may indicate before your next appointment. Take a free, instant, online symptom check to clarify what's going on and confidently navigate your next steps.
Reviewed for medical accuracy: 07/09/2026
Glaucoma is a leading cause of irreversible vision loss. In a subtype called neovascular glaucoma, new, fragile blood vessels grow on the iris and drainage angle, blocking fluid outflow and raising intraocular pressure (IOP). Pan-retinal photocoagulation (PRP for glaucoma) is an established laser treatment that can halt this process and help preserve your vision.
• Pan-retinal photocoagulation (PRP) uses laser burns across the peripheral retina
• It is primarily indicated in proliferative diabetic retinopathy or retinal vein occlusion—conditions that fuel neovascular glaucoma
• By treating a large retinal area, PRP reduces the retina's oxygen demand and cuts production of vascular endothelial growth factor (VEGF), the key driver of unwanted new blood vessels
VEGF Reduction
• Ischemic retina produces excess VEGF
• PRP destroys patches of peripheral retina, lowering VEGF levels
• Existing abnormal vessels regress, and new growth slows
Pressure Control
• Neovascular membranes in the drainage angle block fluid outflow
• As vessels shrink, the angle re-opens slightly, improving IOP
• Lower IOP means less stress on the optic nerve
Preventing Synechiae
• Fibrous tissue can form permanent adhesions (synechiae) that seal the angle
• Early PRP reduces inflammation and vessel proliferation, preventing angle closure
Pre-Treatment Evaluation
Procedure
Post-Treatment Care
While PRP is generally safe, it carries some risks:
Your eye specialist will balance these risks against the threat of irreversible glaucoma-related vision loss.
Comprehensive Evaluation
Medical Management
Anti-VEGF Therapy
Laser Treatment (PRP for Glaucoma)
Surgical Options
Lifelong Monitoring
Even with PRP and medical therapy, neovascular glaucoma can worsen. Contact your eye doctor if you experience:
If you notice any of these warning signs or other concerning changes in your vision, use Ubie's free AI Symptom Checker to quickly assess your symptoms and receive guidance on the urgency of care you may need.
PRP for glaucoma is a powerful tool to save sight in neovascular cases, but individual treatment plans vary. Always speak to a doctor about any eye symptoms that could signal serious or sight-threatening problems. Early diagnosis and a coordinated care approach offer the best chance to preserve your vision.
(References)
* Alio JL, et al. Therapeutic potential of platelet-rich plasma in ophthalmology: a systematic review. Eye (Lond). 2017 Jul;31(7):1001-1011. doi: 10.1038/eye.2017.38. Epub 2017 Mar 24. PMID: 28338686.
* Aftab U, et al. Platelet-rich plasma: a novel therapy for neurodegenerative diseases of the eye? Neural Regen Res. 2021 May;16(5):989-994. doi: 10.4103/1673-5374.301018. PMID: 33269784.
* Park DY, et al. Neuroprotective effects of platelet-rich plasma against oxidative stress-induced retinal ganglion cell damage. Exp Eye Res. 2020 Jan;190:107875. doi: 10.1016/j.exer.2019.107875. Epub 2019 Nov 13. PMID: 31733364.
* Shen T, et al. Clinical application of platelet-rich plasma in ophthalmology. Biomed Res Int. 2021 Dec 21;2021:5548325. doi: 10.1155/2021/5548325. eCollection 2021. PMID: 34966779.
* Zhang Y, et al. Platelet-Rich Plasma in Ophthalmology: Recent Advances and Future Directions. J Ophthalmol. 2023 Feb 15;2023:6630040. doi: 10.1155/2023/6630040. eCollection 2023. PMID: 36824982.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.